Participant flow

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma · Source last updated 2020-09-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cycle 1: Cyclophosphamide 300 mg/m\^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m\^2 continuous IV Days 1-3. Doxil 25 mg/m\^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m\^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14. Cycle 2: Methotrexate 200 mg/m\^2 over 2 hours on Day 1 and 800 mg/m\^2 over 22 hours on day 1. Cytarabine 3 Gm/m\^2 IV twice a day on Days 2 and 3.

   id

   FG000

   title

   HCVIDDOXIL Regimen

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         13

      type

      Disease Progression

   2. reasons

      1. group Id

         FG000

         num Subjects

         14

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Non-Compliance

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Congestive Heart Failure

   6. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Transplant in CR

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Unrelated Infection/Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         53

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         17

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         36

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Of the 55 participants registered, two participants were found not to be eligible prior to start of study therefore are excluded from trial details.

recruitment Details

Recruitment period: September 17, 2003 to May 8, 2009. All recruitment done at The University of Texas MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice